Brain Energy Metabolism Changes and Neuropsychological Impairment in Parkinson Disease vs Alzheimer Disease

Core Pathologies and Shared Neuropsychiatric Features

Alzheimer’s disease features the buildup of amyloid-beta plaques and neurofibrillary tangles that disrupt neuronal communication and lead to progressive cognitive decline. Parkinson’s disease centers on the loss of dopamine-producing neurons in the substantia nigra, accompanied by alpha-synuclein aggregates known as Lewy bodies. Beyond these hallmark motor and memory issues, both disorders frequently involve attention deficits, executive dysfunction, language difficulties, depression, anxiety, apathy, sleep disturbances, and hallucinations. The authors emphasize that these shared symptoms point to common underlying mechanisms, particularly those involving energy supply to brain cells.

Energy metabolism relies on glycolysis in the cytoplasm and oxidative phosphorylation within mitochondria to generate adenosine triphosphate, the cell’s primary energy currency. Interruptions at any stage, including the tricarboxylic acid cycle, can reduce ATP availability and trigger neuronal stress or death. In Alzheimer’s disease, impaired glucose uptake and reduced expression of glucose transporters appear early. In Parkinson’s disease, mitochondrial impairment directly limits ATP production in vulnerable dopaminergic neurons.

Mitochondrial Networks and Their Vulnerability

Neurons depend heavily on mitochondria not only for ATP but also for calcium buffering, reactive oxygen species regulation, and signaling pathways that influence cell survival. The chapter details how mitochondrial networks in neurons form intricate systems that become compromised in both diseases. In Alzheimer’s disease, reduced cytochrome c oxidase activity and elevated oxidative stress markers appear in affected brain regions. In Parkinson’s disease, complex I dysfunction in the electron transport chain has long been linked to selective neuronal loss in the substantia nigra.

These mitochondrial changes do not occur in isolation. They interact with protein aggregation pathways, amplifying damage. The publication notes that early metabolic alterations may precede visible protein deposits, suggesting that bioenergetic failure could represent an initiating event rather than a secondary consequence.

Regional Patterns of Hypometabolism

Imaging studies reveal distinct yet overlapping patterns of reduced glucose utilization. In Alzheimer’s disease, hypometabolism often emerges first in the hippocampus and parietal lobes, correlating with memory and visuospatial deficits. Parkinson’s disease shows prominent changes in the striatum and frontal areas, aligning with motor planning and executive function difficulties. The authors review evidence from arterial spin labeling and positron emission tomography that demonstrates both shared frontal-posterior hypoperfusion and disease-specific signatures.

Astrocytic contributions to energy supply, particularly through aerobic glycolysis and lactate shuttling to neurons, also differ between the conditions. These regional and cellular distinctions help explain why certain neuropsychological profiles predominate in each disease while others overlap.

Photo by Shawn Day on Unsplash

Linking Metabolic Disruption to Cognitive and Psychiatric Symptoms

Reduced ATP availability impairs synaptic transmission, long-term potentiation, and the maintenance of ion gradients essential for neuronal firing. In Alzheimer’s disease, early hippocampal hypometabolism associates with episodic memory loss and language impairments. Executive dysfunction and attention deficits appear as parietal and frontal regions become affected. Neuropsychiatric symptoms such as depression and apathy may stem from disrupted monoaminergic systems that themselves require substantial energy.

Parkinson’s disease patients experience similar cognitive challenges alongside motor symptoms. Mitochondrial failure in the substantia nigra extends to cortical areas, contributing to bradyphrenia, visuospatial problems, and mood disorders. The chapter synthesizes findings showing that metabolic markers can improve diagnostic precision when combined with clinical and molecular data.

Comparative Insights Across the Two Conditions

While both diseases exhibit mitochondrial dysfunction and glucose hypometabolism, the tempo and regional emphasis differ. Alzheimer’s disease tends toward earlier and more diffuse cortical involvement, whereas Parkinson’s disease features more focal subcortical changes that spread over time. Shared pathways include oxidative stress, impaired autophagy, and inflammation that further drain cellular energy reserves.

The authors stress that these parallels open opportunities for cross-disease therapeutic strategies. Metabolic interventions targeting mitochondrial biogenesis, ketone utilization, or glucose transporter function could benefit patients with either diagnosis. Diagnostic tools that integrate neuroenergetic imaging with traditional biomarkers may also enhance early detection.

Therapeutic and Diagnostic Opportunities

The publication outlines how understanding energy metabolism opens avenues for intervention. Strategies under investigation include enhancing mitochondrial quality control, supporting alternative fuel sources such as ketones, and protecting against oxidative damage. Lifestyle factors including exercise and dietary patterns that support metabolic flexibility receive attention as potential adjuncts.

From a diagnostic standpoint, combining cerebrospinal fluid lactate measurements, advanced imaging of glucose and ketone metabolism, and neuropsychological testing could refine staging and prognosis. The chapter calls for longitudinal studies that track metabolic changes alongside clinical progression in both diseases.

Implications for Neuroscience Research and Academic Careers

This work arrives at a time when funding agencies and institutions increasingly prioritize interdisciplinary approaches to neurodegeneration. Researchers with expertise in mitochondrial biology, neuroimaging, and neuropsychology are well positioned for collaborative projects. Academic departments seeking to expand programs in aging and brain health may find this line of inquiry particularly compelling for grant applications and graduate training.

Postdoctoral fellows and early-career investigators can explore metabolic imaging techniques or cellular models that bridge Parkinson’s disease and Alzheimer’s disease. The emphasis on early bioenergetic changes suggests opportunities for preventive or disease-modifying research that appeals to both basic scientists and clinician-researchers.

Photo by KOMMERS on Unsplash

Future Directions and Broader Context

The authors conclude by noting the need for integrated models that incorporate genetic risk factors, environmental influences, and systemic metabolic health. Advances in single-cell metabolomics and organoid models offer new tools to dissect cell-type-specific energy demands. International collaborations will be essential given the global burden of these diseases.

Public health perspectives underscore the value of metabolic health promotion across the lifespan as a potential population-level strategy. Educational initiatives aimed at clinicians and caregivers can incorporate emerging insights about energy metabolism to improve patient management.

Conclusion

The chapter by Khodadadi and colleagues provides a timely synthesis of how brain energy metabolism alterations contribute to the neuropsychological landscape of Parkinson’s disease and Alzheimer’s disease. By highlighting both convergent and divergent mechanisms, it charts a path toward more precise diagnostics and targeted interventions. Academics and clinicians engaged in neurodegenerative research will find valuable frameworks for future inquiry in this publication.